Syndivia's vision is to deliver the best treatment to cancer patients by harnessing unique properties of tumour hallmarks and microenvironment.

Three unparalleled technologies

Controlled protein fusion, tumour microenvironment drug release,
stable conjugation

DARX
Scalable industrial process for stochiometric chemical protein fusion

C&R
Hypoxic and necrotic tumour microenvironment-specific drug release

APN
Plasma-stable
cysteine conjugation

Two lead programs

SDV1001
Pancreatic cancer, colorectal cancer, TNBC
First-in-man in 2019

SDV1101
Breast cancer, liposarcoma
First-in-man in 2021


+ Multiple partnered preclinical programs

Board of directors

445A4268-web-800.jpg
Jean-Yves Bonnefoy
Chairman
445A4240-web-800.jpg
Sasha Koniev
CEO
445A4256-web-800.jpg
Sergii Kolodych
CSO

 

Scientific advisory board

Dr Alain Wagner
Bioconjugation
University of Strasbourg
Prof Sebastien Papot
Drug release
University of Poitiers
Dr Frederic Taran
Bioorthogonal chemistry
CEA Saclay
Dr Alain Van Dorsselaer
Bioanalytics
University of Strasbourg

Our Office

Syndivia
650 Boulevard Gonthier d'Andernach
Parc d'Innovation, 67400 Illkirch, France

Tel: +33 3 67 10 42 20
Fax: +33 3 67 10 42 06
Email: enquiry@syndivia.com

 

 
 

Contact Us

Feel free to send us an email or use the contact form to leave your message. Our representative will get in touch with you shortly after.

Name *
Name